Trademark Overview
On Monday, November 6, 2023, a trademark application was filed for LIQUI SRS with the United States Patent and Trademark Office. The USPTO has given the LIQUI SRS trademark a serial number of 98256227. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, January 23, 2025. This trademark is owned by EMOVIAR PharmaCon GmbH. The LIQUI SRS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical drugs for the treatment and prevention of chronic and non-chronic diseases, namely, pain diseases, cardiovascular diseases, cancer diseases, infectious diseases, neural diseases, respiratory diseases, obesity diseases, and kidney diseases; Drug delivery agents in particular sustained release agents in the form of capsules and tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drugs for medical for purposes in particular sustained release drug formulations for the treatment and prevention of chronic and non-chronic diseases, namely, pain diseases, cardiovascular diseases, cancer diseases, infectious diseases, neural diseases, respiratory diseases, obesity diseases, and kidney diseases
Drug discovery services; biological research; clinical research in the medical, pharmaceutical, and biotechnology fields; medical research; research on the subject of pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; research and development in the pharmaceutical and biotechnology fields for the pharmaceutical industry; pharmaceutical products development; pharmaceutical formulation in the nature of pharmaceutical products development; biomedical research services; medical and scientific research in the field of pharmacogenetics; research and development of vaccines and medicines; pharmaceutical drug development services; development of pharmaceutical preparations in particular sustained release formulations and medicines; pharmaceutical research services.
